Year |
Citation |
Score |
2023 |
Tilaki EH, Hasanzadeh A, Shalbafan M, Moghaddam HS, Shamabadi A, Boroon M, Akhondzadeh S. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180. PMID 37747999 DOI: 10.1097/WNF.0000000000000564 |
0.31 |
|
2023 |
Tilaki EH, Hasanzadeh A, Shalbafan M, Moghaddam HS, Shamabadi A, Boroon M, Akhondzadeh S. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clinical Neuropharmacology. 46: 175-180. PMID 37747999 DOI: 10.1097/WNF.0000000000000564 |
0.31 |
|
2023 |
Ansari S, Sanjari Moghaddam H, Basti FA, Salehi M, Akhondzadeh S. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research. 174: 111471. PMID 37660680 DOI: 10.1016/j.jpsychores.2023.111471 |
0.332 |
|
2023 |
Nasiri M, Parmoon Z, Farahmand Y, Moradi A, Farahmand K, Moradi K, Basti FA, Mohammadi MR, Akhondzadeh S. l-carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial. International Clinical Psychopharmacology. PMID 37551601 DOI: 10.1097/YIC.0000000000000496 |
0.339 |
|
2023 |
Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S. L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences. PMID 37169515 DOI: 10.1111/pcn.13565 |
0.33 |
|
2023 |
Shamabadi A, Kafi F, Arab Bafrani M, Asadigandomani H, A Basti F, Akhondzadeh S. l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Journal of Affective Disorders. 333: 38-43. PMID 37084960 DOI: 10.1016/j.jad.2023.04.029 |
0.346 |
|
2022 |
Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. Iranian Journal of Psychiatry. 17: 320-340. PMID 36474699 DOI: 10.18502/ijps.v17i3.9733 |
0.334 |
|
2022 |
Ebrahimi P, Seyedmirzaei H, Moradi K, Bagheri S, Moeini M, Mohammadi MR, Akhondzadeh S. Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial. International Clinical Psychopharmacology. PMID 36165508 DOI: 10.1097/YIC.0000000000000431 |
0.355 |
|
2022 |
Abbasian F, Bagheri S, Moradi K, Keykhaei M, Etemadi A, Shalbafan M, Shariati B, Vaseghi S, Samsami FS, Akhondzadeh S. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial. Clinical Neuropharmacology. 45: 128-134. PMID 36093920 DOI: 10.1097/WNF.0000000000000518 |
0.32 |
|
2022 |
Zandifar A, Badrfam R, Sanjari Moghaddam H, Akhondzadeh S. Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. Iranian Journal of Psychiatry. 17: 14-23. PMID 35480128 DOI: 10.18502/ijps.v17i1.8045 |
0.387 |
|
2022 |
Motamed M, Karimi H, Sanjari Moghaddam H, Taherzadeh Boroujeni S, Sanatian Z, Hasanzadeh A, Khodaei Ardakani MR, Akhondzadeh S. Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. 37: 92-101. PMID 35258035 DOI: 10.1097/YIC.0000000000000399 |
0.371 |
|
2022 |
Talaei A, Dastgheib MS, Soltanifar A, Mokhber N, Akhondzadeh S, Afzaljavan F. Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial. International Clinical Psychopharmacology. PMID 35121700 DOI: 10.1097/YIC.0000000000000394 |
0.373 |
|
2022 |
Khadivi A, Shobeiri P, Momtazmaneh S, Samsami FS, Shalbafan M, Shirazi E, Akhondzadeh S. Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial. Psychopharmacology. 239: 551-559. PMID 35072758 DOI: 10.1007/s00213-021-06041-0 |
0.359 |
|
2022 |
Zarezadeh F, Arbabi M, Shamabadi A, Naderi S, Hasanzadeh A, Ostadpour M, Samsami FS, Akhondzadeh S. Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. International Clinical Psychopharmacology. 37: 46-53. PMID 34864756 DOI: 10.1097/YIC.0000000000000383 |
0.392 |
|
2021 |
Badrfam R, Mostafavi SA, Khaleghi A, Akhondzadeh S, Zandifar A, Farid M, Mohammadian Khonsari N, Mohammadi MR. The efficacy of vitamin B6 as an adjunctive therapy to lithium in improving the symptoms of acute mania in patients with bipolar disorder, type 1; a double-blind, randomized, placebo-controlled, clinical trial. Brain and Behavior. 11: e2394. PMID 34662000 DOI: 10.1002/brb3.2394 |
0.316 |
|
2021 |
Shamabadi A, Akhondzadeh S. Efficacy and tolerability of in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. Journal of Complementary & Integrative Medicine. PMID 34420270 DOI: 10.1515/jcim-2020-0498 |
0.335 |
|
2021 |
Zandifar A, Badrfam R, Shamabadi A, Jalilevand S, Pourmirbabaei S, Torkamand F, Sahebolzamani E, Akhondzadeh S. Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry. 16: 52-59. PMID 34054983 DOI: 10.18502/ijps.v16i1.5379 |
0.408 |
|
2021 |
Masoudi M, Ansari S, Kashani L, Tavolinejad H, Hossein Rashidi B, Esalatmanesh S, Ghazizadeh-Hashemi M, Noorbala AA, Akhondzadeh S. Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial. International Clinical Psychopharmacology. PMID 34030169 DOI: 10.1097/YIC.0000000000000367 |
0.316 |
|
2021 |
Farajollahi-Moghadam M, Sanjari-Moghaddam H, Ghazizadeh Hasemi M, Sanatian Z, Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. 36: 140-146. PMID 33724254 DOI: 10.1097/YIC.0000000000000353 |
0.414 |
|
2020 |
Noroozi A, Motevalian SA, Zarrindast MR, Alaghband-Rad J, Akhondzadeh S. Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial. Medical Journal of the Islamic Republic of Iran. 34: 137. PMID 33437733 DOI: 10.34171/mjiri.34.137 |
0.341 |
|
2020 |
Hoobehfekr S, Moghaddam HS, Shalbafan M, Hashemi MG, Pirmoradi MM, Sakenian A, Poopak A, Kashefinejad S, Yarahmadi M, Akhondzadeh S. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences. PMID 33247483 DOI: 10.1111/pcn.13180 |
0.322 |
|
2020 |
Batebi N, Moghaddam HS, Hasanzadeh A, Fakour Y, Mohammadi MR, Akhondzadeh S. Folinic Acid as Adjunctive Therapy in Treatment of Inappropriate Speech in Children with Autism: A Double-Blind and Placebo-Controlled Randomized Trial. Child Psychiatry and Human Development. PMID 33029705 DOI: 10.1007/s10578-020-01072-8 |
0.319 |
|
2020 |
Ghamari K, Kashani L, Jafarinia M, Tadayon Najafabadi B, Shokraee K, Esalatmanesh S, Akhondzadeh S. Vitamin E and ginseng supplementation to enhance female sexual function: a randomized, double-blind, placebo-controlled, clinical trial. Women & Health. 60: 1164-1173. PMID 32893745 DOI: 10.1080/03630242.2020.1803465 |
0.367 |
|
2020 |
Moradi K, Ashraf-Ganjouei A, Tavolinejad H, Bagheri S, Akhondzadeh S. The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110091. PMID 32891667 DOI: 10.1016/J.Pnpbp.2020.110091 |
0.301 |
|
2020 |
Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi MR, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clinical Neuropharmacology. PMID 32815851 DOI: 10.1097/Wnf.0000000000000405 |
0.382 |
|
2020 |
Firoozeei TS, Barekatain M, Karimi M, Zargaran A, Akhondzadeh S, Rezaeizadeh H. Lavender and dodder combined herbal syrup versus citalopram in major depressive disorder with anxious distress: A double-blind randomized trial. Journal of Integrative Medicine. PMID 32739466 DOI: 10.1016/J.Joim.2020.06.002 |
0.42 |
|
2020 |
Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, Shalbafan MR, Ghaffari S, Alikhani R, Mousavi SB, Naderi S, Shamabadi A, Jalilevand S, Akhondzadeh S. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. International Clinical Psychopharmacology. 35: 254-262. PMID 32541380 DOI: 10.1097/Yic.0000000000000321 |
0.505 |
|
2020 |
Rafeiy-Torghabeh M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. European Child & Adolescent Psychiatry. PMID 32449130 DOI: 10.1007/S00787-020-01562-Z |
0.415 |
|
2020 |
Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi-Shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics. PMID 32420649 DOI: 10.1111/Jcpt.13177 |
0.441 |
|
2020 |
Momtazmanesh S, Amirimoghaddam-Yazdi Z, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences. 74: 398-405. PMID 32347624 DOI: 10.1111/Pcn.13016 |
0.435 |
|
2020 |
Talaei A, Hosseini FF, Aghili Z, Akhondzadeh S, Asadpour E, Mehramiz NJ, Forouzanfar F. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Canadian Journal of Physiology and Pharmacology. 236-242. PMID 32228235 DOI: 10.1139/Cjpp-2019-0381 |
0.454 |
|
2020 |
Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. Clinical Neuropharmacology. 43: 39-45. PMID 32168067 DOI: 10.1097/Wnf.0000000000000382 |
0.409 |
|
2020 |
Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology (Oxford, England). 34: 506-513. PMID 32122230 DOI: 10.1177/0269881120909416 |
0.431 |
|
2020 |
Araminia B, Shalbafan M, Mortezaei A, Shirazi E, Ghaffari S, Sahebolzamani E, Mortazavi SH, Shariati B, Ardebili ME, Aqamolaei A, Naderi S, Akhondzadeh S. L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 267: 131-136. PMID 32063564 DOI: 10.1016/J.Jad.2020.02.020 |
0.436 |
|
2020 |
Moghaddam HS, Bahmani S, Bayanati S, Mahdavinasa M, Rezaei F, Akhondzadeh S. Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial. International Clinical Psychopharmacology. 35: 81-88. PMID 31743233 DOI: 10.1097/Yic.0000000000000298 |
0.508 |
|
2020 |
Behmanesh H, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clinical Neuropharmacology. 42: 189-196. PMID 31725473 DOI: 10.1097/Wnf.0000000000000368 |
0.458 |
|
2020 |
Shakiba M, Moazen-Zadeh E, Noorbala AA, Jafarinia M, Divsalar P, Kashani L, Shahmansouri N, Tafakhori A, Bayat H, Akhondzadeh S. Saffron () versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. Avicenna Journal of Phytomedicine. 8: 513-523. PMID 30456199 |
0.371 |
|
2020 |
Arabzadeh S, Zeinoddini A, Mostafavi SA, Hamedi M, Ehyaii A, Ghaleiha A, Zeinoddini A, Akhondzadeh S. Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Iranian Journal of Psychiatry. 13: 1-9. PMID 29892311 |
0.357 |
|
2020 |
Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Akhondzadeh S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Bozorgi A. Atomoxetine in patients with recurrent vasovagal syncope for preventing vasovagal attacks and improvement of depression and anxiety: a randomized double-blind placebo-controlled clinical trial European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.0713 |
0.332 |
|
2020 |
Ghaffari S, Ghobadi A, Jamshidi AH, Mortazavi SH, Naderi S, Aqamolaei A, Mortezaei A, Sahebolzamani E, Shamabadi A, Jalilvand S, Daraei B, Shalbafan MR, Akhondzadeh S. Cinnamomum tamala as an adjuvant therapy in the treatment of major depressive disorder: A double-blind, randomized, placebo-controlled clinical trial with placebo control Advances in Integrative Medicine. 7: 141-147. DOI: 10.1016/J.Aimed.2019.12.002 |
0.545 |
|
2019 |
Kianbakht S, Hajiaghaee R, Akhondzadeh S. Efficacy and safety of Sophora alopecuroides var. alopecuroides seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial. Phytotherapy Research : Ptr. 34: 1108-1113. PMID 31793731 DOI: 10.1002/Ptr.6578 |
0.369 |
|
2019 |
Hendouei F, Sanjari Moghaddam H, Mohammadi MR, Taslimi N, Rezaei F, Akhondzadeh S. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. Journal of Clinical Pharmacy and Therapeutics. 45: 324-334. PMID 31714621 DOI: 10.1111/Jcpt.13076 |
0.453 |
|
2019 |
Ahmadpanah M, Ramezanshams F, Ghaleiha A, Akhondzadeh S, Sadeghi Bahmani D, Brand S. Crocus Sativus L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders-a double-blind, randomized intervention study. Psychiatry Research. 282: 112613. PMID 31669837 DOI: 10.1016/J.Psychres.2019.112613 |
0.367 |
|
2019 |
Talaei A, Forouzanfar F, Akhondzadeh S. Medicinal plants in the treatment of obsessive-compulsive disorder: A review. Current Drug Discovery Technologies. PMID 31660838 DOI: 10.2174/1570163816666191011105050 |
0.335 |
|
2019 |
Akhondzadeh S, Mostafavi SA, Keshavarz SA, Mohammadi MR, Hosseini S, Eshraghian MR. A placebo controlled randomized clinical trial of Crocus sativus L. (saffron) on depression and food craving among overweight women with mild to moderate depression. Journal of Clinical Pharmacy and Therapeutics. PMID 31602695 DOI: 10.1111/Jcpt.13040 |
0.349 |
|
2019 |
Shalbafan M, Malekpour F, Tadayon Najafabadi B, Ghamari K, Dastgheib SA, Mowla A, Shirazi E, Eftekhar Ardebili M, Ghazizadeh-Hashemi M, Akhondzadeh S. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. Journal of Psychopharmacology (Oxford, England). 33: 1407-1414. PMID 31575326 DOI: 10.1177/0269881119878177 |
0.439 |
|
2019 |
Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA, Ebrahimi Daryani N, Kashani L, Akhondzadeh S. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 45: 97-104. PMID 31486103 DOI: 10.1111/Jcpt.13032 |
0.356 |
|
2019 |
Motaharifard MS, Effatpanah M, Karimi M, Akhondzadeh S, Rahimi H, Yasrebi SA, Nejatbakhsh F. Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. Complementary Therapies in Clinical Practice. 36: 170-175. PMID 31383435 DOI: 10.1016/J.Ctcp.2019.07.008 |
0.361 |
|
2019 |
Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S. Efficacy and Safety of Tipepidine as Adjunctive Therapy in Children with Attention-Deficit / Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Psychiatry and Clinical Neurosciences. PMID 31294924 DOI: 10.1111/Pcn.12913 |
0.404 |
|
2019 |
Mahdavinasab SM, Saghazadeh A, Motamed-Gorji N, Vaseghi S, Mohammadi MR, Alichani R, Akhondzadeh S. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. European Child & Adolescent Psychiatry. 28: 1619-1628. PMID 30980177 DOI: 10.1007/S00787-019-01333-5 |
0.414 |
|
2019 |
Baziar S, Aqamolaei A, Khadem E, Mortazavi SH, Naderi S, Sahebolzamani E, Mortezaei A, Jalilevand S, Mohammadi MR, Shahmirzadi M, Akhondzadeh S. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study. Journal of Child and Adolescent Psychopharmacology. 29: 205-212. PMID 30741567 DOI: 10.1089/Cap.2018.0146 |
0.395 |
|
2019 |
Nikoo M, Moazen-Zadeh E, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Givaki R, Jazani M, Mohammadian F, Markazi Moghaddam N, Goudarzi N, Schutz C, ... ... Akhondzadeh S, et al. Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. International Journal of Methods in Psychiatric Research. e1768. PMID 30714249 DOI: 10.1002/Mpr.1768 |
0.4 |
|
2019 |
Najafabadi BT, Jafarinia M, Ghamari K, Shokraee K, Tadayyon F, Akhondzadeh S. Vitamin E and ginseng combined supplement for treatment of male erectile dysfunction: a double-blind, placebo-controlled, randomized, clinical trial Advances in Integrative Medicine. DOI: 10.1016/J.Aimed.2019.12.001 |
0.403 |
|
2019 |
Tadyon Najafabadi B, Ghamari K, Kermany Ranjabari T, Noorbala AA, Ebrahimi Daryani N, Vanaki E, Akhondzadeh S. Therapeutic effects of saffron (Crocus sativus) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial Advances in Integrative Medicine. 6: 167-173. DOI: 10.1016/J.Aimed.2019.01.001 |
0.435 |
|
2018 |
Farahzadi MH, Moazen-Zadeh E, Razaghi E, Zarrindast MR, Bidaki R, Akhondzadeh S. Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology (Oxford, England). 33: 305-315. PMID 30526230 DOI: 10.1177/0269881118817166 |
0.398 |
|
2018 |
Naderi S, Faghih H, Aqamolaei A, Mortazavi SH, Mortezaei A, Sahebolzamani E, Rezaei F, Akhondzadeh S. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control. Psychiatry and Clinical Neurosciences. 73: 169-174. PMID 30488617 DOI: 10.1111/Pcn.12803 |
0.483 |
|
2018 |
Milajerdi A, Jazayeri S, Shirzadi E, Hashemzadeh N, Azizgol A, Djazayery A, Esmaillzadeh A, Akhondzadeh S. The effects of alcoholic extract of saffron (Crocus satious L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial. Complementary Therapies in Medicine. 41: 196-202. PMID 30477839 DOI: 10.1016/J.Ctim.2018.09.023 |
0.372 |
|
2018 |
Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, Nejatisafa AA, Sadat-Shirazi MS, Zarrindast MR. Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiology & Behavior. 195: 151-157. PMID 30107190 DOI: 10.1016/J.Physbeh.2018.08.002 |
0.391 |
|
2018 |
Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Human Psychopharmacology. 33: e2662. PMID 29901250 DOI: 10.1002/Hup.2662 |
0.434 |
|
2018 |
Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH, Laksari FY, Hosseini M, Mohammadi MR, Akhondzadeh S. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. Journal of Psychiatric Research. 103: 104-111. PMID 29807317 DOI: 10.1016/J.Jpsychires.2018.04.022 |
0.479 |
|
2018 |
Keshavarz SA, Mostafavi SA, Akhondzadeh S, Mohammadi MR, Hosseini S, Eshraghian MR, Chamari M. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clinical Nutrition Espen. 25: 37-43. PMID 29779816 DOI: 10.1016/J.Clnesp.2018.03.001 |
0.341 |
|
2018 |
Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, Akhondzadeh S. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. Journal of Affective Disorders. 235: 236-241. PMID 29660637 DOI: 10.1016/J.Jad.2018.02.056 |
0.425 |
|
2018 |
Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, Ghaleiha A, Ardebili ME, Akhondzadeh S. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. Journal of Affective Disorders. 232: 127-133. PMID 29486338 DOI: 10.1016/J.Jad.2018.02.057 |
0.448 |
|
2018 |
Ghajar A, Aghajan-Nashtaei F, Afarideh M, Mohammadi MR, Akhondzadeh S. l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Child and Adolescent Psychopharmacology. 28: 331-338. PMID 29469593 DOI: 10.1089/Cap.2017.0157 |
0.379 |
|
2018 |
Ghajar A, Khoaie-Ardakani MR, Shahmoradi Z, Alavi AR, Afarideh M, Shalbafan MR, Ghazizadeh-Hashemi M, Akhondzadeh S. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Psychiatry Research. 262: 94-101. PMID 29427913 DOI: 10.1016/J.Psychres.2018.02.012 |
0.483 |
|
2018 |
Kashani L, Esalatmanesh S, Eftekhari F, Salimi S, Foroughifar T, Etesam F, Safiaghdam H, Moazen-Zadeh E, Akhondzadeh S. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Archives of Gynecology and Obstetrics. PMID 29332222 DOI: 10.1007/S00404-018-4655-2 |
0.461 |
|
2018 |
Shakiba M, Moazenzadeh E, Noorbala AA, Jafarinia M, Divsalar P, Kashani L, Shahmansouri N, Tafakhori A, Bayat H, Akhondzadeh S. Saffron ( Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial Avicenna Journal of Phytomedicine. 8: 513-523. DOI: 10.22038/Ajp.2018.28835.2020 |
0.48 |
|
2018 |
Divsalar P, Noorbala AA, Moazen-Zadeh E, Jafarinia M, Shakiba M, Shahmansouri N, Ghazizadeh-Hashemi M, Etesam F, Akhondzadeh S. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: Placebo-controlled trial Advances in Integrative Medicine. 5: 69-74. DOI: 10.1016/J.Aimed.2018.01.001 |
0.479 |
|
2017 |
Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, Hajhosseinn Talasaz A, Salehiomran A, Forghani S, Akhondzadeh S. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. Journal of Alternative and Complementary Medicine (New York, N.Y.). PMID 29185780 DOI: 10.1089/Acm.2017.0173 |
0.33 |
|
2017 |
Morabbi MJ, Razaghi E, Moazen-Zadeh E, Safiaghdam H, Zarrindast MR, Vousoghi N, Akhondzadeh S. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. PMID 29064909 DOI: 10.1097/Yic.0000000000000200 |
0.508 |
|
2017 |
Esalatmanesh S, Biuseh M, Noorbala AA, Mostafavi SA, Rezaei F, Mesgarpour B, Mohammadinejad P, Akhondzadeh S. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. Iranian Journal of Psychiatry. 12: 154-162. PMID 29062366 |
0.376 |
|
2017 |
Hajizadeh-Zaker R, Ghajar A, Mesgarpour B, Afarideh M, Mohammadi MR, Akhondzadeh S. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 29027815 DOI: 10.1089/Cap.2017.0026 |
0.378 |
|
2017 |
Moazen-Zadeh E, Shirzad F, Karkhaneh-Yousefi MA, Khezri R, Mohammadi MR, Akhondzadeh S. Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Child and Adolescent Psychopharmacology. PMID 28719227 DOI: 10.1089/Cap.2017.0055 |
0.448 |
|
2017 |
Kashani L, Shams N, Moazen-Zadeh E, Karkhaneh-Yousefi MA, Sadighi G, Khodaie-Ardakani MR, Rezaei F, Rahiminejad F, Akhondzadeh S. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. Journal of Psychiatric Research. 94: 70-77. PMID 28688338 DOI: 10.1016/J.Jpsychires.2017.06.011 |
0.475 |
|
2017 |
Alamdarsaravi M, Ghajar A, Noorbala AA, Arbabi M, Emami A, Shahei F, Mirzania M, Jafarinia M, Afarideh M, Akhondzadeh S. Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. Psychiatry Research. 255: 59-65. PMID 28528242 DOI: 10.1016/J.Psychres.2017.05.029 |
0.486 |
|
2017 |
Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Human Psychopharmacology. PMID 28485008 DOI: 10.1002/Hup.2584 |
0.356 |
|
2017 |
Rezaei F, Mesgarpour B, Jeddian A, Zeionoddini A, Mohammadinejad P, Salardini E, Shahriari M, Zeinoddini A, Akhondzadeh S. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human Psychopharmacology. PMID 28421639 DOI: 10.1002/Hup.2583 |
0.397 |
|
2017 |
Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, Mohammadinejad P, Gholamian F, Mohammadi MR, Zeinoddini A, Akhondzadeh S. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania. Journal of Child and Adolescent Psychopharmacology. PMID 28409660 DOI: 10.1089/Cap.2016.0207 |
0.382 |
|
2017 |
Mostafavi SA, Solhi M, Mohammadi MR, Akhondzadeh S. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 28339282 DOI: 10.1089/Cap.2016.0046 |
0.407 |
|
2017 |
Roohi-Azizi M, Arabzadeh S, Amidfar M, Salimi S, Zarindast MR, Talaei A, Akhondzadeh S. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Neuropharmacology. 40: 1-5. PMID 28085707 DOI: 10.1097/Wnf.0000000000000185 |
0.438 |
|
2017 |
Milajerdi A, Jazayeri S, Bitarafan V, Hashemzadeh N, Shirzadi E, Derakhshan Z, Mahmoodi M, Rayati A, Djazayeri A, Akhondzadeh S. The effect of saffron ( Crocus sativus L.) hydro-alcoholic extract on liver and renal functions in type 2 diabetic patients: A double-blinded randomized and placebo control trial Journal of Nutrition & Intermediary Metabolism. 9: 6-11. DOI: 10.1016/J.Jnim.2017.07.002 |
0.314 |
|
2016 |
Akhondzadeh S, Moazen-Zadeh E. More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia. Evidence-Based Mental Health. PMID 28011708 DOI: 10.1136/Eb-2016-102500 |
0.472 |
|
2016 |
Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B, Akhondzadeh S. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. International Clinical Psychopharmacology. PMID 27941358 DOI: 10.1097/Yic.0000000000000159 |
0.449 |
|
2016 |
Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics. PMID 27809351 DOI: 10.1111/Jcpt.12469 |
0.453 |
|
2016 |
Ghajar A, Neishabouri SM, Velayati N, Jahangard L, Matinnia N, Haghighi M, Ghaleiha A, Afarideh M, Salimi S, Meysamie A, Akhondzadeh S. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry. 50: 152-160. PMID 27701683 DOI: 10.1055/S-0042-116159 |
0.487 |
|
2016 |
Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, Hosseinian M, Foroughifar T, Salimi S, Akhondzadeh S. Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. Pharmacopsychiatry. 50: 64-68. PMID 27595298 DOI: 10.1055/S-0042-115306 |
0.484 |
|
2016 |
Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan MR, Shalbafan MR, Akhondzadeh S. Minocycline combination therapy with fluvoxamine in moderate to severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neurosciences. PMID 27488081 DOI: 10.1111/Pcn.12430 |
0.447 |
|
2016 |
Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA, Saravi MA, Agah E, Akhondzadeh S. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. Journal of Affective Disorders. 204: 1-8. PMID 27317968 DOI: 10.1016/J.Jad.2016.05.076 |
0.393 |
|
2016 |
Salardini E, Zeinoddini A, Kohi A, Mohammadi MR, Mohammadinejad P, Khiabany M, Shahriari M, Akhondzadeh S. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial. Journal of Child and Adolescent Psychopharmacology. PMID 27286139 DOI: 10.1089/Cap.2016.0024 |
0.387 |
|
2016 |
Khajehnasiri F, Akhondzadeh S, Mortazavi SB, Allameh A, Sotoudeh G, Khavanin A, Zamanian Z. Are Supplementation of Omega-3 and Ascorbic Acid Effective in Reducing Oxidative Stress and Depression among Depressed Shift Workers? International Journal For Vitamin and Nutrition Research. Internationale Zeitschrift Fur Vitamin- Und Ernahrungsforschung. Journal International De Vitaminologie Et De Nutrition. 1-12. PMID 27164176 DOI: 10.1024/0300-9831/A000249 |
0.304 |
|
2016 |
Ghaleiha A, Alikhani R, Kazemi MR, Mohammadi MR, Mohammadinejad P, Zeinoddini A, Hamedi M, Shahriari M, Keshavarzi Z, Akhondzadeh S. Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. PMID 27128958 DOI: 10.1089/Cap.2015.0175 |
0.403 |
|
2016 |
Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive Compulsive Disorder: Randomized, Double-blind, Placebo-Controlled Study. Psychiatry and Clinical Neurosciences. PMID 27106362 DOI: 10.1111/Pcn.12394 |
0.478 |
|
2016 |
Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 41: 214-9. PMID 26931055 DOI: 10.1111/Jcpt.12370 |
0.443 |
|
2016 |
Nikbakhat M-, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A, Akhondzadeh S. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. Pharmacopsychiatry. 49: 162-169. PMID 26902281 DOI: 10.1055/S-0042-101557 |
0.467 |
|
2016 |
Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeionoddini A, Mohammadinejad P, Zeinoddini A, Akhondzadeh S. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Human Psychopharmacology. PMID 26856695 DOI: 10.1002/Hup.2517 |
0.384 |
|
2016 |
Salardini E, Zeinoddini A, Mohammadinejad P, Khodaie-Ardakani MR, Zahraei N, Zeinoddini A, Akhondzadeh S. Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research. 75: 24-30. PMID 26800392 DOI: 10.1016/J.Jpsychires.2016.01.003 |
0.534 |
|
2015 |
Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, Rasoulinejad M, Zeinoddini A, Yalda A, Akhondzadeh S. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. International Clinical Psychopharmacology. PMID 26465919 DOI: 10.1097/Yic.0000000000000098 |
0.435 |
|
2015 |
Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P. Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial. Pharmacopsychiatry. PMID 26398281 DOI: 10.1055/S-0035-1559667 |
0.378 |
|
2015 |
Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disorders. 17: 606-14. PMID 26291962 DOI: 10.1111/Bdi.12324 |
0.389 |
|
2015 |
Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Research. PMID 26208985 DOI: 10.1016/J.Psychres.2015.07.043 |
0.457 |
|
2015 |
Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami SA, Akhondzadeh S. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. The Annals of Pharmacotherapy. PMID 26139640 DOI: 10.1177/1060028015592215 |
0.32 |
|
2015 |
Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M, Akhondzadeh S. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia. Acta Medica Iranica. 53: 337-45. PMID 26069170 |
0.386 |
|
2015 |
Jafari S, Ashrafizadeh SG, Zeinoddini A, Rasoulinejad M, Entezari P, Seddighi S, Akhondzadeh S. Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. Journal of Clinical Pharmacy and Therapeutics. 40: 441-6. PMID 26009929 DOI: 10.1111/Jcpt.12287 |
0.389 |
|
2015 |
Abbasi SH, Mohammadinejad P, Shahmansouri N, Salehiomran A, Beglar AA, Zeinoddini A, Forghani S, Akhondzadeh S. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders. 183: 149-55. PMID 26005776 DOI: 10.1016/J.Jad.2015.04.049 |
0.347 |
|
2015 |
Shalbafan M, Mohammadinejad P, Shariat SV, Alavi K, Zeinoddini A, Salehi M, Askari N, Akhondzadeh S. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. Pharmacopsychiatry. 48: 136-40. PMID 25959196 DOI: 10.1055/S-0035-1549929 |
0.417 |
|
2015 |
Gougol A, Zareh-Mohammadi N, Raheb S, Farokhnia M, Salimi S, Iranpour N, Yekehtaz H, Akhondzadeh S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 29: 575-81. PMID 25827645 DOI: 10.1177/0269881115578160 |
0.491 |
|
2015 |
Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depression and Anxiety. 32: 167-73. PMID 25620378 DOI: 10.1002/Da.22340 |
0.425 |
|
2015 |
Rezaei F, Emami M, Zahed S, Morabbi MJ, Farahzadi M, Akhondzadeh S. Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 23: 2. PMID 25588930 DOI: 10.1186/S40199-015-0092-Y |
0.475 |
|
2015 |
Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology. 38: 11-7. PMID 25580916 DOI: 10.1097/Wnf.0000000000000063 |
0.425 |
|
2015 |
Vafaeinasab MR, Farahzadi MH, Razaghi OM, Fallahzadeh RA, Lotfi MH, Akhondzadeh S. Investigation of Affecting Factors on Persistence in the Treatment of Patients under Methadone Maintenance Therapy in Addiction Therapy Centers, Yazd-Iran Health. 7: 606-616. DOI: 10.4236/Health.2015.75072 |
0.327 |
|
2014 |
Mostafavi A, Solhi M, Mohammadi MR, Hamedi M, Keshavarzi M, Akhondzadeh S. Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Medica Iranica. 52: 734-9. PMID 25369006 |
0.314 |
|
2014 |
Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. Journal of Psychiatric Research. 59: 125-31. PMID 25227564 DOI: 10.1016/J.Jpsychires.2014.08.016 |
0.45 |
|
2014 |
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, Farsad F, Kamalipour M, Akhondzadeh S. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Human Psychopharmacology. 29: 351-9. PMID 25163440 DOI: 10.1002/Hup.2412 |
0.328 |
|
2014 |
Ghanizadeh A, Rezaee Z, Dehbozorgi S, Berk M, Akhondzadeh S. Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Psychiatry Research. 219: 431-5. PMID 25017614 DOI: 10.1016/J.Psychres.2014.06.039 |
0.467 |
|
2014 |
Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 22: 55. PMID 25012765 DOI: 10.1186/2008-2231-22-55 |
0.456 |
|
2014 |
Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. Journal of Affective Disorders. 166: 201-5. PMID 25012432 DOI: 10.1016/J.Jad.2014.05.015 |
0.485 |
|
2014 |
Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. International Clinical Psychopharmacology. 29: 344-50. PMID 24850229 DOI: 10.1097/Yic.0000000000000043 |
0.484 |
|
2014 |
Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 846-55. PMID 24636461 DOI: 10.1016/J.Euroneuro.2014.02.001 |
0.478 |
|
2014 |
Kargar M, Yousefi A, Mojtahedzadeh M, Akhondzadeh S, Artounian V, Abdollahi A, Ahmadvand A, Ghaeli P. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Medical Weekly. 144: w13880. PMID 24554598 DOI: 10.4414/Smw.2014.13880 |
0.407 |
|
2014 |
Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M, Akhondzadeh S. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Research. 215: 540-6. PMID 24480077 DOI: 10.1016/J.Psychres.2013.12.051 |
0.455 |
|
2014 |
Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. Journal of Affective Disorders. 155: 216-22. PMID 24289892 DOI: 10.1016/J.Jad.2013.11.003 |
0.449 |
|
2014 |
Yoosefi A, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, Alimadadi A, Ghaeli P. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. The Journal of Ect. 30: 15-21. PMID 24091902 DOI: 10.1097/Yct.0B013E3182A4B4C6 |
0.438 |
|
2014 |
Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacology. 231: 533-42. PMID 24013610 DOI: 10.1007/S00213-013-3261-Z |
0.409 |
|
2013 |
Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology. 36: 185-92. PMID 24201233 DOI: 10.1097/Wnf.0000000000000001 |
0.437 |
|
2013 |
Mohammadi MR, Yadegari N, Hassanzadeh E, Farokhnia M, Yekehtaz H, Mirshafiee O, Akhondzadeh S. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology. 36: 179-84. PMID 24201232 DOI: 10.1097/Wnf.0B013E3182A9339D |
0.477 |
|
2013 |
Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, Yadegari N, Tabrizi M, Hajiaghaee R, Yekehtaz H, Akhondzadeh S. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 28: 677-685. PMID 24132248 DOI: 10.1177/0269881113508830 |
0.476 |
|
2013 |
Saroukhani S, Emami-Parsa M, Modabbernia A, Ashrafi M, Farokhnia M, Hajiaghaee R, Akhondzadeh S. Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disorders. 15: 650-6. PMID 23924261 DOI: 10.1111/Bdi.12108 |
0.461 |
|
2013 |
Khajehnasiri F, Mortazavi SB, Allameh A, Akhondzadeh S. Effect of omega-3 and ascorbic acid on inflammation markers in depressed shift workers in Shahid Tondgoyan Oil Refinery, Iran: a randomized double-blind placebo-controlled study. Journal of Clinical Biochemistry and Nutrition. 53: 36-40. PMID 23874068 DOI: 10.3164/Jcbn.12-98 |
0.364 |
|
2013 |
Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz H, Ashrafi M, Hassanzadeh E, Akhondzadeh S. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatric Drugs. 15: 505-14. PMID 23821414 DOI: 10.1007/S40272-013-0036-2 |
0.477 |
|
2013 |
Khajehnasiri F, Mortazavi SB, Allameh A, Akhondzadeh S, Hashemi H. Total antioxidant capacity and malondialdehyde in depressive rotational shift workers. Journal of Environmental and Public Health. 2013: 150693. PMID 23690799 DOI: 10.1155/2013/150693 |
0.312 |
|
2013 |
Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 33: 336-42. PMID 23609382 DOI: 10.1097/Jcp.0B013E31828B50A7 |
0.501 |
|
2013 |
Akhondzadeh S, Gerbarg PL, Brown RP. Nutrients for prevention and treatment of mental health disorders. The Psychiatric Clinics of North America. 36: 25-36. PMID 23538074 DOI: 10.1016/J.Psc.2012.12.003 |
0.424 |
|
2013 |
Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Rezaei F, Salehi B, Ashrafi M, Yekehtaz H, Tabrizi M, Akhondzadeh S. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. 228: 595-602. PMID 23515583 DOI: 10.1007/S00213-013-3064-2 |
0.448 |
|
2013 |
Dabaghzadeh F, Ghaeli P, Khalili H, Alimadadi A, Jafari S, Akhondzadeh S, Khazaeipour Z. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. Aids Patient Care and Stds. 27: 146-54. PMID 23442031 DOI: 10.1089/Apc.2012.0410 |
0.417 |
|
2013 |
Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research. 47: 472-8. PMID 23375406 DOI: 10.1016/J.Jpsychires.2013.01.011 |
0.484 |
|
2013 |
Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human Psychopharmacology. 28: 54-60. PMID 23280545 DOI: 10.1002/Hup.2282 |
0.377 |
|
2013 |
Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. Cns Drugs. 27: 57-65. PMID 23233269 DOI: 10.1007/S40263-012-0022-1 |
0.458 |
|
2013 |
Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. Journal of Psychiatric Research. 47: 175-80. PMID 23063327 DOI: 10.1016/J.Jpsychires.2012.09.015 |
0.486 |
|
2013 |
Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, Hassanzadeh E, Akhondzadeh S. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 783-9. PMID 22999292 DOI: 10.1017/S1461145712000880 |
0.464 |
|
2013 |
Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 38: 767-76. PMID 22999261 DOI: 10.1016/J.Psyneuen.2012.08.010 |
0.407 |
|
2013 |
Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, Forghani S, Akhondzadeh S. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 225: 51-9. PMID 22782459 DOI: 10.1007/S00213-012-2796-8 |
0.429 |
|
2012 |
Faghihi T, Jahed A, Mahmoudi-Gharaei J, Sharifi V, Akhondzadeh S, Ghaeli P. Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial. Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 20: 43. PMID 23351198 DOI: 10.1186/2008-2231-20-43 |
0.387 |
|
2012 |
Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study. Acta Medica Iranica. 50: 723-8. PMID 23292622 |
0.342 |
|
2012 |
Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 73: 1428-33. PMID 23146150 DOI: 10.4088/Jcp.12M07706 |
0.51 |
|
2012 |
Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. Cns Drugs. 26: 883-92. PMID 22873680 DOI: 10.2165/11635850-000000000-00000 |
0.454 |
|
2012 |
Jafarinia M, Mohammadi MR, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, Yadegari N, Akhondzadeh S. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Human Psychopharmacology. 27: 411-8. PMID 22806822 DOI: 10.1002/Hup.2242 |
0.408 |
|
2012 |
Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, Jamshidi A, Tabrizi M, Ashrafi M, Akhondzadeh S. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. 223: 381-8. PMID 22552758 DOI: 10.1007/S00213-012-2729-6 |
0.471 |
|
2012 |
Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2093-100. PMID 22549115 DOI: 10.1038/Npp.2012.58 |
0.482 |
|
2012 |
Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. Journal of Affective Disorders. 141: 308-14. PMID 22516310 DOI: 10.1016/J.Jad.2012.03.033 |
0.39 |
|
2012 |
Hasanzadeh E, Mohammadi MR, Ghanizadeh A, Rezazadeh SA, Tabrizi M, Rezaei F, Akhondzadeh S. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry and Human Development. 43: 674-82. PMID 22392415 DOI: 10.1007/S10578-012-0292-3 |
0.455 |
|
2012 |
Arbabi M, Bagheri M, Rezaei F, Ahmadi-Abhari SA, Tabrizi M, Khalighi-Sigaroudi F, Akhondzadeh S. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology. 220: 591-8. PMID 21947320 DOI: 10.1007/S00213-011-2513-Z |
0.472 |
|
2012 |
Khajehnasiri F, Mortazavi SB, Allameh AA, Akhondzadeh S. Serum Level of Cortisol, hsCRP and IL-6 in Depressed Rotational Shift Workers Thrita Journal of Medical Sciences. 1: 139-44. DOI: 10.5812/Thrita.8644 |
0.312 |
|
2011 |
Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depression and Anxiety. 28: 297-302. PMID 21456039 DOI: 10.1002/Da.20801 |
0.517 |
|
2011 |
Ghaleiha A, Honarbakhsh N, Boroumand MA, Jafarinia M, Tabrizi M, Rezaei F, Raznahan M, Akhondzadeh S. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Human Psychopharmacology. 26: 120-4. PMID 21412846 DOI: 10.1002/Hup.1176 |
0.403 |
|
2011 |
Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, Ghaleiha A, Akhondzadeh S. Acetyl-L-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry and Human Development. 42: 367-75. PMID 21336630 DOI: 10.1007/S10578-011-0220-Y |
0.432 |
|
2011 |
Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology. 213: 809-15. PMID 20949350 DOI: 10.1007/S00213-010-2044-Z |
0.475 |
|
2011 |
Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Ahmadi-Abhari SA, Sadeghi M, Tabrizi M, Akhondzadeh S. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Affective Disorders. 129: 327-31. PMID 20843556 DOI: 10.1016/J.Jad.2010.08.015 |
0.475 |
|
2011 |
Jafari P, Ghanizadeh A, Akhondzadeh S, Mohammadi MR. Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 20: 31-6. PMID 20686924 DOI: 10.1007/S11136-010-9722-5 |
0.307 |
|
2011 |
Mohammadi MR, Salmanian M, Akhondzadeh S. Autism spectrum disorders in Iran Iranian Journal of Child Neurology. 5: 1-9. DOI: 10.5772/38965 |
0.326 |
|
2011 |
Davari-Ashtiani R, Parvaresh N, Akhondzadeh S. Gabapentin as a combination treatment with lithium in adolescents with bipolar disorder International Clinical Psychopharmacology. 26: e40. DOI: 10.1097/01.Yic.0000405697.15125.C1 |
0.316 |
|
2011 |
Modabbernia A, Ashrafi M, Rahiminejad F, Akhondzadeh S. Fc22-04 Effect of folic acid add-on treatment in patients with acute mania on clinical symptoms and urinary 6-sulfatoxymelatonin: double blind placebo-controlled trial European Psychiatry. 26: 1937-1937. DOI: 10.1016/S0924-9338(11)73641-0 |
0.423 |
|
2010 |
Mohammadi MR, Kazemi MR, Zia E, Rezazadeh SA, Tabrizi M, Akhondzadeh S. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Human Psychopharmacology. 25: 560-5. PMID 21312290 DOI: 10.1002/Hup.1154 |
0.451 |
|
2010 |
Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology. 30: 678-82. PMID 21105281 DOI: 10.1097/Jcp.0B013E3181Fa8720 |
0.486 |
|
2010 |
Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Human Psychopharmacology. 25: 530-5. PMID 20860068 DOI: 10.1002/Hup.1148 |
0.451 |
|
2010 |
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 35: 581-8. PMID 20831681 DOI: 10.1111/J.1365-2710.2009.01133.X |
0.411 |
|
2010 |
Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, Akhondzadeh S. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1269-72. PMID 20637249 DOI: 10.1016/J.Pnpbp.2010.07.005 |
0.45 |
|
2010 |
Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia Research. 116: 101-6. PMID 19959338 DOI: 10.1016/J.Schres.2009.11.008 |
0.459 |
|
2010 |
Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology. 207: 637-43. PMID 19838862 DOI: 10.1007/S00213-009-1706-1 |
0.415 |
|
2010 |
Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 76-80. PMID 19815048 DOI: 10.1016/J.Pnpbp.2009.09.026 |
0.421 |
|
2010 |
Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, Raznahan M, Mohebbi-Rasa S, Rezazadeh SA, Forghani S. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 32-6. PMID 19772883 DOI: 10.1016/J.Pnpbp.2009.09.012 |
0.45 |
|
2009 |
Salmasi FB, Jazayeri M, Ghaeli P, Hashemian F, Akhondzadeh S, Raisi F, Hosseini SH, Setareh MJ, Khavidaki SD. Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine. Journal of Clinical Psychopharmacology. 29: 182-3. PMID 19512983 DOI: 10.1097/Jcp.0B013E31819A6Aa2 |
0.313 |
|
2009 |
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety. 26: 607-11. PMID 19496103 DOI: 10.1002/Da.20589 |
0.485 |
|
2009 |
Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Research. 168: 234-7. PMID 19439364 DOI: 10.1016/J.Psychres.2008.06.024 |
0.429 |
|
2009 |
Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophrenia Research. 107: 206-12. PMID 18789844 DOI: 10.1016/J.Schres.2008.08.004 |
0.42 |
|
2008 |
Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 1879-83. PMID 18801405 DOI: 10.1016/J.Pnpbp.2008.08.020 |
0.452 |
|
2008 |
Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, Rezazadeh SA. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 1810-5. PMID 18727948 DOI: 10.1016/J.Pnpbp.2008.08.001 |
0.449 |
|
2008 |
Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. Bjog : An International Journal of Obstetrics and Gynaecology. 115: 515-9. PMID 18271889 DOI: 10.1111/J.1471-0528.2007.01652.X |
0.473 |
|
2008 |
Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Mohammadi MR, Noorbala AA, Ahmadi-Abhari SA, Hajiazim M, Abbasi SH, Akhondzadeh S. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 726-32. PMID 18096287 DOI: 10.1016/J.Pnpbp.2007.11.021 |
0.462 |
|
2008 |
Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human Psychopharmacology. 23: 79-86. PMID 17972359 DOI: 10.1002/Hup.902 |
0.457 |
|
2008 |
Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, Ghelichnia HA. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry and Human Development. 39: 237-45. PMID 17929164 DOI: 10.1007/S10578-007-0084-3 |
0.469 |
|
2008 |
Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 145-9. PMID 17765380 DOI: 10.1016/J.Pnpbp.2007.07.025 |
0.42 |
|
2008 |
Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial: Baclofen versus clonidine Journal of Clinical Pharmacy and Therapeutics. 26: 67-71. DOI: 10.1111/J.1365-2710.2001.00325.X |
0.42 |
|
2008 |
Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal: Baclofen versus clonidine for opiate withdrawal Journal of Clinical Pharmacy and Therapeutics. 25: 347-353. DOI: 10.1111/J.1365-2710.2000.00295.X |
0.406 |
|
2007 |
Togha M, Akhondzadeh S, Motamedi M, Ahmadi B, Razeghi S. Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial. Archives of Medical Research. 38: 313-6. PMID 17350481 DOI: 10.1016/J.Arcmed.2006.10.010 |
0.385 |
|
2007 |
Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Review of Neurotherapeutics. 7: 195-201. PMID 17286552 DOI: 10.1586/14737175.7.2.195 |
0.348 |
|
2007 |
Rokni-Yazdi H, Sotoudeh H, Akhondzadeh S, Sotoudeh E, Asadi H, Shakiba M. Antidepressant-like effect of magnetic resonance imaging-based stimulation in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31: 503-9. PMID 17218047 DOI: 10.1016/J.Pnpbp.2006.11.021 |
0.301 |
|
2007 |
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research. 90: 179-85. PMID 17208413 DOI: 10.1016/J.Schres.2006.11.016 |
0.462 |
|
2007 |
Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31: 439-42. PMID 17174460 DOI: 10.1016/J.Pnpbp.2006.11.010 |
0.479 |
|
2007 |
Raisi F, Habibi N, Nasehi AA, Akhondzadeh S. Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial Therapy. 4: 187-192. DOI: 10.2217/14750708.4.2.187 |
0.442 |
|
2007 |
Mohammadi MR, Akhondzadeh S. Autism spectrum disorders: Etiology and pharmacotherapy Current Drug Therapy. 2: 97-103. DOI: 10.2174/157488507780619095 |
0.333 |
|
2007 |
Akhondzadeh S. Herbal medicines in the treatment of psychiatric and neurological disorders Low-Cost Approaches to Promote Physical and Mental Health: Theory, Research, and Practice. 119-138. DOI: 10.1007/0-387-36899-X_6 |
0.386 |
|
2006 |
Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disorders. 8: 485-9. PMID 17042886 DOI: 10.1111/J.1399-5618.2006.00363.X |
0.497 |
|
2006 |
Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 13: 607-11. PMID 16979327 DOI: 10.1016/J.Phymed.2006.08.006 |
0.498 |
|
2006 |
Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophrenia Research. 84: 405-10. PMID 16545544 DOI: 10.1016/J.Schres.2006.02.008 |
0.374 |
|
2006 |
Akhondzadeh S. Pharmacotherapy of Schizophrenia: The Past, Present and Future Current Drug Therapy. 1: 1-7. DOI: 10.2174/157488506775268461 |
0.336 |
|
2005 |
Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Research : Ptr. 19: 148-51. PMID 15852492 DOI: 10.1002/Ptr.1647 |
0.497 |
|
2005 |
Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. Journal of Clinical Pharmacy and Therapeutics. 30: 133-8. PMID 15811165 DOI: 10.1111/J.1365-2710.2004.00585.X |
0.486 |
|
2005 |
Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. Journal of Ethnopharmacology. 97: 281-4. PMID 15707766 DOI: 10.1016/J.Jep.2004.11.004 |
0.481 |
|
2005 |
Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29: 253-9. PMID 15694232 DOI: 10.1016/J.Pnpbp.2004.11.008 |
0.478 |
|
2005 |
Akhondzadeh S, Mokhberi K, Amini H, Larijani B, Kashani L, Hashemi L, Nejatisafa AA, Shafaei AR. Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia? Therapy. 2: 745-751. DOI: 10.2217/14750708.2.5.745 |
0.365 |
|
2005 |
Akhondzadeh S, Milajerdi MR, Amini H, Moin M, Bathaei FS, Kamlipour A. Allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients Therapy. 2: 739-744. DOI: 10.2217/14750708.2.5.739 |
0.506 |
|
2005 |
Akhondzadeh S, Mohammadi MR, Momeni F. Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents Therapy. 2: 609-614. DOI: 10.2217/14750708.2.4.609 |
0.437 |
|
2005 |
Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia? Therapy. 2: 399-406. DOI: 10.2217/14750708.2.3.399 |
0.372 |
|
2004 |
Soleimani A, Moayyeri A, Akhondzadeh S, Sadatsafavi M, Tavakoli Shalmani H, Soltanzadeh A. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. Bmc Neurology. 4: 12. PMID 15361260 DOI: 10.1186/1471-2377-4-12 |
0.363 |
|
2004 |
Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. Bmc Complementary and Alternative Medicine. 4: 12. PMID 15341662 DOI: 10.1186/1472-6882-4-12 |
0.475 |
|
2004 |
Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. Bmc Psychiatry. 4: 9. PMID 15070418 DOI: 10.1186/1471-244X-4-9 |
0.467 |
|
2004 |
Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 29: 145-50. PMID 15068403 DOI: 10.1111/J.1365-2710.2004.00546.X |
0.47 |
|
2004 |
Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics. 29: 139-44. PMID 15068402 DOI: 10.1111/J.1365-2710.2004.00545.X |
0.436 |
|
2004 |
Mohammadi MR, Ghanizadeh A, Rahgozar M, Noorbala AA, Davidian H, Afzali HM, Naghavi HR, Yazdi SA, Saberi SM, Mesgarpour B, Akhondzadeh S, Alaghebandrad J, Tehranidoost M. Prevalence of obsessive-compulsive disorder in Iran. Bmc Psychiatry. 4: 2. PMID 15018627 DOI: 10.1186/1471-244X-4-2 |
0.301 |
|
2004 |
Saiiah Bargard M, Assadi SM, Amini H, Saiiah M, Akhondzadeh S, Kamalinejad M. Efficacy of aqueous extract of Echium amoenum L. in the treatment of mild to moderate major depressive disorder: A randomized double blind clinical trial Journal of Medicinal Plants. 3: 61-68+XIX. |
0.345 |
|
2004 |
Noorbala AA, Tahmasebi-Pour N, Akhondzadeh S, Khani M, Jamshidi AH. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomised and placebo controlled trial Journal of Medicinal Plants. 3: 31-38+XV. |
0.323 |
|
2003 |
Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. Journal of Clinical Pharmacy and Therapeutics. 28: 379-84. PMID 14632962 DOI: 10.1046/J.0269-4727.2003.00505.X |
0.445 |
|
2003 |
Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F, Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 1007-12. PMID 14499318 DOI: 10.1016/S0278-5846(03)00161-1 |
0.461 |
|
2003 |
Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 841-5. PMID 12921918 DOI: 10.1016/S0278-5846(03)00117-9 |
0.413 |
|
2003 |
Akhondzadeh S. Hydroxyzine may be safe and effective in generalised anxiety disorder. Evidence-Based Mental Health. 6: 91. PMID 12893802 DOI: 10.1136/Ebmh.6.3.91 |
0.318 |
|
2003 |
Akhondzadeh S, Mohajari H, Reza Mohammadi M, Amini H. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. Bmc Psychiatry. 3: 7. PMID 12816549 DOI: 10.1186/1471-244X-3-7 |
0.504 |
|
2003 |
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry. 74: 863-6. PMID 12810768 DOI: 10.1136/Jnnp.74.7.863 |
0.395 |
|
2003 |
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 28: 53-9. PMID 12605619 DOI: 10.1046/J.1365-2710.2003.00463.X |
0.362 |
|
2003 |
Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri M, Moin M, Khani M, Jamshidi AH, Baghalian K, Taghizadeh M. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 123-7. PMID 12551734 DOI: 10.1016/S0278-5846(02)00342-1 |
0.491 |
|
2002 |
Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 27: 453-9. PMID 12472985 DOI: 10.1046/J.1365-2710.2002.00445.X |
0.399 |
|
2002 |
Gudarzi SS, Yasamy M, Akhondzadeh S. Cyproheptadine in treatment of autism. European Psychiatry : the Journal of the Association of European Psychiatrists. 17: 230-1. PMID 12231270 DOI: 10.1016/S0924-9338(02)00662-4 |
0.309 |
|
2001 |
Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics. 26: 369-73. PMID 11679027 DOI: 10.1046/J.1365-2710.2001.00366.X |
0.443 |
|
2001 |
Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics. 26: 363-7. PMID 11679026 DOI: 10.1046/J.1365-2710.2001.00367.X |
0.46 |
|
2001 |
Ahmadi-Abhari SA, Akhondzadeh S, Assadi SM, Shabestari OL, Farzanehgan ZM, Kamlipour A. Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics. 26: 67-71. PMID 11286609 DOI: 10.1046/J.1365-2710.2001.00325.X |
0.456 |
|
2000 |
Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics. 25: 347-53. PMID 11123486 DOI: 10.1046/J.1365-2710.2000.00295.X |
0.401 |
|
1999 |
Akhondzadeh S, Emamian ES, Ahmadi-Abhari A, Shabestari O, Dadgarnejad M. Is it time to have another look at lithium maintenance therapy in bipolar disorder? Progress in Neuro-Psychopharmacology & Biological Psychiatry. 23: 1011-7. PMID 10621946 DOI: 10.1016/S0278-5846(99)00056-1 |
0.364 |
|
1999 |
Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 24: 369-74. PMID 10583700 DOI: 10.1046/J.1365-2710.1999.00238.X |
0.408 |
|
1999 |
Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics. 24: 49-52. PMID 10319907 DOI: 10.1046/J.1365-2710.1999.00197.X |
0.435 |
|
1998 |
Noorbala AA, Hosseini SH, Mohammadi MR, Akhondzadeh S. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 23: 155-9. PMID 9786103 |
0.412 |
|
Show low-probability matches. |